Global Primary Biliary Cirrhosis Drug Market Research Report 2024

Report ID: 1977484 | Published Date: Jan 2025 | No. of Page: 92 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Primary Biliary Cirrhosis Drug Market Overview
    1.1 Product Overview and Scope of Primary Biliary Cirrhosis Drug
    1.2 Primary Biliary Cirrhosis Drug Segment by Type
        1.2.1 Global Primary Biliary Cirrhosis Drug Market Value Comparison by Type (2023-2029)
        1.2.2 Budesonide
        1.2.3 FFP-104
        1.2.4 GSK-2330672
        1.2.5 MBX-8025
        1.2.6 NGM-282
        1.2.7 Others
    1.3 Primary Biliary Cirrhosis Drug Segment by Application
        1.3.1 Global Primary Biliary Cirrhosis Drug Market Value by Application: (2023-2029)
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 Global Primary Biliary Cirrhosis Drug Market Size Estimates and Forecasts
        1.4.1 Global Primary Biliary Cirrhosis Drug Revenue 2018-2029
        1.4.2 Global Primary Biliary Cirrhosis Drug Sales 2018-2029
        1.4.3 Global Primary Biliary Cirrhosis Drug Market Average Price (2018-2029)
    1.5 Assumptions and Limitations
2 Primary Biliary Cirrhosis Drug Market Competition by Manufacturers
    2.1 Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2018-2023)
    2.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Manufacturers (2018-2023)
    2.3 Global Primary Biliary Cirrhosis Drug Average Price by Manufacturers (2018-2023)
    2.4 Global Primary Biliary Cirrhosis Drug Industry Ranking 2021 VS 2022 VS 2023
    2.5 Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Manufacturing Sites & Headquarters
    2.6 Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Product Type & Application
    2.7 Primary Biliary Cirrhosis Drug Market Competitive Situation and Trends
        2.7.1 Primary Biliary Cirrhosis Drug Market Concentration Rate
        2.7.2 The Global Top 5 and Top 10 Largest Primary Biliary Cirrhosis Drug Players Market Share by Revenue
        2.7.3 Global Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary Biliary Cirrhosis Drug Retrospective Market Scenario by Region
    3.1 Global Primary Biliary Cirrhosis Drug Market Size by Region: 2018 Versus 2022 Versus 2029
    3.2 Global Primary Biliary Cirrhosis Drug Global Primary Biliary Cirrhosis Drug Sales by Region: 2018-2029
        3.2.1 Global Primary Biliary Cirrhosis Drug Sales by Region: 2018-2023
        3.2.2 Global Primary Biliary Cirrhosis Drug Sales by Region: 2024-2029
    3.3 Global Primary Biliary Cirrhosis Drug Global Primary Biliary Cirrhosis Drug Revenue by Region: 2018-2029
        3.3.1 Global Primary Biliary Cirrhosis Drug Revenue by Region: 2018-2023
        3.3.2 Global Primary Biliary Cirrhosis Drug Revenue by Region: 2024-2029
    3.4 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
        3.4.1 North America Primary Biliary Cirrhosis Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.4.2 North America Primary Biliary Cirrhosis Drug Sales by Country (2018-2029)
        3.4.3 North America Primary Biliary Cirrhosis Drug Revenue by Country (2018-2029)
        3.4.4 U.S.
        3.4.5 Canada
    3.5 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
        3.5.1 Europe Primary Biliary Cirrhosis Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.5.2 Europe Primary Biliary Cirrhosis Drug Sales by Country (2018-2029)
        3.5.3 Europe Primary Biliary Cirrhosis Drug Revenue by Country (2018-2029)
        3.5.4 Germany
        3.5.5 France
        3.5.6 U.K.
        3.5.7 Italy
        3.5.8 Russia
    3.6 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
        3.6.1 Asia Pacific Primary Biliary Cirrhosis Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.6.2 Asia Pacific Primary Biliary Cirrhosis Drug Sales by Country (2018-2029)
        3.6.3 Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Country (2018-2029)
        3.6.4 China
        3.6.5 Japan
        3.6.6 South Korea
        3.6.7 India
        3.6.8 Australia
        3.6.9 Taiwan
        3.6.10 Indonesia
        3.6.11 Thailand
        3.6.12 Malaysia
        3.6.13 Philippines
    3.7 Latin America Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
        3.7.1 Latin America Primary Biliary Cirrhosis Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.7.2 Latin America Primary Biliary Cirrhosis Drug Sales by Country (2018-2029)
        3.7.3 Latin America Primary Biliary Cirrhosis Drug Revenue by Country (2018-2029)
        3.7.4 Mexico
        3.7.5 Brazil
        3.7.6 Argentina
    3.8 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
        3.8.1 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size by Country: 2018 VS 2022 VS 2029
        3.8.2 Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2018-2029)
        3.8.3 Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country (2018-2029)
        3.8.4 Turkey
        3.8.5 Saudi Arabia
        3.8.6 UAE
4 Segment by Type
    4.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2018-2029)
        4.1.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2018-2023)
        4.1.2 Global Primary Biliary Cirrhosis Drug Sales by Type (2024-2029)
        4.1.3 Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2018-2029)
    4.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2018-2029)
        4.2.1 Global Primary Biliary Cirrhosis Drug Revenue by Type (2018-2023)
        4.2.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2024-2029)
        4.2.3 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2029)
    4.3 Global Primary Biliary Cirrhosis Drug Price by Type (2018-2029)
5 Segment by Application
    5.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2018-2029)
        5.1.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2018-2023)
        5.1.2 Global Primary Biliary Cirrhosis Drug Sales by Application (2024-2029)
        5.1.3 Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2018-2029)
    5.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2018-2029)
        5.2.1 Global Primary Biliary Cirrhosis Drug Revenue by Application (2018-2023)
        5.2.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2024-2029)
        5.2.3 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2029)
    5.3 Global Primary Biliary Cirrhosis Drug Price by Application (2018-2029)
6 Key Companies Profiled
    6.1 AlbireoPharma
        6.1.1 AlbireoPharma Corporation Information
        6.1.2 AlbireoPharma Description and Business Overview
        6.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
        6.1.5 AlbireoPharma Recent Developments/Updates
    6.2 CymaBay Therapeutics, Inc.
        6.2.1 CymaBay Therapeutics, Inc. Corporation Information
        6.2.2 CymaBay Therapeutics, Inc. Description and Business Overview
        6.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
        6.2.5 CymaBay Therapeutics, Inc. Recent Developments/Updates
    6.3 Dr. Falk Pharma GmbH
        6.3.1 Dr. Falk Pharma GmbH Corporation Information
        6.3.2 Dr. Falk Pharma GmbH Description and Business Overview
        6.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
        6.3.5 Dr. Falk Pharma GmbH Recent Developments/Updates
    6.4 Enanta Pharmaceuticals, Inc.
        6.4.1 Enanta Pharmaceuticals, Inc. Corporation Information
        6.4.2 Enanta Pharmaceuticals, Inc. Description and Business Overview
        6.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
        6.4.5 Enanta Pharmaceuticals, Inc. Recent Developments/Updates
    6.5 GlaxoSmithKline Plc
        6.5.1 GlaxoSmithKline Plc Corporation Information
        6.5.2 GlaxoSmithKline Plc Description and Business Overview
        6.5.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
        6.5.5 GlaxoSmithKline Plc Recent Developments/Updates
    6.6 Intercept Pharmaceuticals, Inc.
        6.6.1 Intercept Pharmaceuticals, Inc. Corporation Information
        6.6.2 Intercept Pharmaceuticals, Inc. Description and Business Overview
        6.6.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.6.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
        6.6.5 Intercept Pharmaceuticals, Inc. Recent Developments/Updates
    6.7 Johnson & Johnson
        6.6.1 Johnson & Johnson Corporation Information
        6.6.2 Johnson & Johnson Description and Business Overview
        6.6.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.4.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
        6.7.5 Johnson & Johnson Recent Developments/Updates
    6.8 MediGene AG
        6.8.1 MediGene AG Corporation Information
        6.8.2 MediGene AG Description and Business Overview
        6.8.3 MediGene AG Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.8.4 MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
        6.8.5 MediGene AG Recent Developments/Updates
    6.9 NGM Biopharmaceuticals, Inc.
        6.9.1 NGM Biopharmaceuticals, Inc. Corporation Information
        6.9.2 NGM Biopharmaceuticals, Inc. Description and Business Overview
        6.9.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.9.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
        6.9.5 NGM Biopharmaceuticals, Inc. Recent Developments/Updates
    6.10 Virobay Inc.
        6.10.1 Virobay Inc. Corporation Information
        6.10.2 Virobay Inc. Description and Business Overview
        6.10.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2023)
        6.10.4 Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio
        6.10.5 Virobay Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
    7.1 Primary Biliary Cirrhosis Drug Industry Chain Analysis
    7.2 Primary Biliary Cirrhosis Drug Key Raw Materials
       7.2.1 Key Raw Materials
       7.2.2 Raw Materials Key Suppliers
    7.3 Primary Biliary Cirrhosis Drug Production Mode & Process
    7.4 Primary Biliary Cirrhosis Drug Sales and Marketing
        7.4.1 Primary Biliary Cirrhosis Drug Sales Channels
        7.4.2 Primary Biliary Cirrhosis Drug Distributors
    7.5 Primary Biliary Cirrhosis Drug Customers
8 Primary Biliary Cirrhosis Drug Market Dynamics
    8.1 Primary Biliary Cirrhosis Drug Industry Trends
    8.2 Primary Biliary Cirrhosis Drug Market Drivers
    8.3 Primary Biliary Cirrhosis Drug Market Challenges
    8.4 Primary Biliary Cirrhosis Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
    10.1 Methodology/Research Approach
        10.1.1 Research Programs/Design
        10.1.2 Market Size Estimation
        10.1.3 Market Breakdown and Data Triangulation
    10.2 Data Source
        10.2.1 Secondary Sources
        10.2.2 Primary Sources
    10.3 Author List
    10.4 Disclaimer

List of Tables
    Table 1. Global Primary Biliary Cirrhosis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global Primary Biliary Cirrhosis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global Primary Biliary Cirrhosis Drug Market Competitive Situation by Manufacturers in 2022
    Table 4. Global Primary Biliary Cirrhosis Drug Sales (K Pcs) of Key Manufacturers (2018-2023)
    Table 5. Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global Primary Biliary Cirrhosis Drug Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market Primary Biliary Cirrhosis Drug Average Price (USD/Pcs) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of Primary Biliary Cirrhosis Drug, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Product Type & Application
    Table 12. Global Key Manufacturers of Primary Biliary Cirrhosis Drug, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Primary Biliary Cirrhosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Biliary Cirrhosis Drug as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Primary Biliary Cirrhosis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global Primary Biliary Cirrhosis Drug Sales by Region (2018-2023) & (K Pcs)
    Table 18. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2018-2023)
    Table 19. Global Primary Biliary Cirrhosis Drug Sales by Region (2024-2029) & (K Pcs)
    Table 20. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2024-2029)
    Table 21. Global Primary Biliary Cirrhosis Drug Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2018-2023)
    Table 23. Global Primary Biliary Cirrhosis Drug Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2024-2029)
    Table 25. North America Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America Primary Biliary Cirrhosis Drug Sales by Country (2018-2023) & (K Pcs)
    Table 27. North America Primary Biliary Cirrhosis Drug Sales by Country (2024-2029) & (K Pcs)
    Table 28. North America Primary Biliary Cirrhosis Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America Primary Biliary Cirrhosis Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe Primary Biliary Cirrhosis Drug Sales by Country (2018-2023) & (K Pcs)
    Table 32. Europe Primary Biliary Cirrhosis Drug Sales by Country (2024-2029) & (K Pcs)
    Table 33. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Region (2018-2023) & (K Pcs)
    Table 37. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Region (2024-2029) & (K Pcs)
    Table 38. Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2018-2023) & (K Pcs)
    Table 42. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2024-2029) & (K Pcs)
    Table 43. Latin America Primary Biliary Cirrhosis Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Primary Biliary Cirrhosis Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Country (2018-2023) & (K Pcs)
    Table 47. Middle East & Africa Primary Biliary Cirrhosis Drug Sales by Country (2024-2029) & (K Pcs)
    Table 48. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global Primary Biliary Cirrhosis Drug Sales (K Pcs) by Type (2018-2023)
    Table 51. Global Primary Biliary Cirrhosis Drug Sales (K Pcs) by Type (2024-2029)
    Table 52. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2018-2023)
    Table 53. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2024-2029)
    Table 54. Global Primary Biliary Cirrhosis Drug Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global Primary Biliary Cirrhosis Drug Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2018-2023)
    Table 57. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2024-2029)
    Table 58. Global Primary Biliary Cirrhosis Drug Price (USD/Pcs) by Type (2018-2023)
    Table 59. Global Primary Biliary Cirrhosis Drug Price (USD/Pcs) by Type (2024-2029)
    Table 60. Global Primary Biliary Cirrhosis Drug Sales (K Pcs) by Application (2018-2023)
    Table 61. Global Primary Biliary Cirrhosis Drug Sales (K Pcs) by Application (2024-2029)
    Table 62. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2018-2023)
    Table 63. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2024-2029)
    Table 64. Global Primary Biliary Cirrhosis Drug Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global Primary Biliary Cirrhosis Drug Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2018-2023)
    Table 67. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2024-2029)
    Table 68. Global Primary Biliary Cirrhosis Drug Price (USD/Pcs) by Application (2018-2023)
    Table 69. Global Primary Biliary Cirrhosis Drug Price (USD/Pcs) by Application (2024-2029)
    Table 70. AlbireoPharma Corporation Information
    Table 71. AlbireoPharma Description and Business Overview
    Table 72. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 73. AlbireoPharma Primary Biliary Cirrhosis Drug Product
    Table 74. AlbireoPharma Recent Developments/Updates
    Table 75. CymaBay Therapeutics, Inc. Corporation Information
    Table 76. CymaBay Therapeutics, Inc. Description and Business Overview
    Table 77. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 78. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product
    Table 79. CymaBay Therapeutics, Inc. Recent Developments/Updates
    Table 80. Dr. Falk Pharma GmbH Corporation Information
    Table 81. Dr. Falk Pharma GmbH Description and Business Overview
    Table 82. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 83. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product
    Table 84. Dr. Falk Pharma GmbH Recent Developments/Updates
    Table 85. Enanta Pharmaceuticals, Inc. Corporation Information
    Table 86. Enanta Pharmaceuticals, Inc. Description and Business Overview
    Table 87. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 88. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product
    Table 89. Enanta Pharmaceuticals, Inc. Recent Developments/Updates
    Table 90. GlaxoSmithKline Plc Corporation Information
    Table 91. GlaxoSmithKline Plc Description and Business Overview
    Table 92. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 93. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product
    Table 94. GlaxoSmithKline Plc Recent Developments/Updates
    Table 95. Intercept Pharmaceuticals, Inc. Corporation Information
    Table 96. Intercept Pharmaceuticals, Inc. Description and Business Overview
    Table 97. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 98. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product
    Table 99. Intercept Pharmaceuticals, Inc. Recent Developments/Updates
    Table 100. Johnson & Johnson Corporation Information
    Table 101. Johnson & Johnson Description and Business Overview
    Table 102. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 103. Johnson & Johnson Primary Biliary Cirrhosis Drug Product
    Table 104. Johnson & Johnson Recent Developments/Updates
    Table 105. MediGene AG Corporation Information
    Table 106. MediGene AG Description and Business Overview
    Table 107. MediGene AG Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 108. MediGene AG Primary Biliary Cirrhosis Drug Product
    Table 109. MediGene AG Recent Developments/Updates
    Table 110. NGM Biopharmaceuticals, Inc. Corporation Information
    Table 111. NGM Biopharmaceuticals, Inc. Description and Business Overview
    Table 112. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 113. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product
    Table 114. NGM Biopharmaceuticals, Inc. Recent Developments/Updates
    Table 115. Virobay Inc. Corporation Information
    Table 116. Virobay Inc. Description and Business Overview
    Table 117. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
    Table 118. Virobay Inc. Primary Biliary Cirrhosis Drug Product
    Table 119. Virobay Inc. Recent Developments/Updates
    Table 120. Key Raw Materials Lists
    Table 121. Raw Materials Key Suppliers Lists
    Table 122. Primary Biliary Cirrhosis Drug Distributors List
    Table 123. Primary Biliary Cirrhosis Drug Customers List
    Table 124. Primary Biliary Cirrhosis Drug Market Trends
    Table 125. Primary Biliary Cirrhosis Drug Market Drivers
    Table 126. Primary Biliary Cirrhosis Drug Market Challenges
    Table 127. Primary Biliary Cirrhosis Drug Market Restraints
    Table 128. Research Programs/Design for This Report
    Table 129. Key Data Information from Secondary Sources
    Table 130. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Primary Biliary Cirrhosis Drug
    Figure 2. Global Primary Biliary Cirrhosis Drug Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global Primary Biliary Cirrhosis Drug Market Share by Type in 2022 & 2029
    Figure 4. Budesonide Product Picture
    Figure 5. FFP-104 Product Picture
    Figure 6. GSK-2330672 Product Picture
    Figure 7. MBX-8025 Product Picture
    Figure 8. NGM-282 Product Picture
    Figure 9. Others Product Picture
    Figure 10. Global Primary Biliary Cirrhosis Drug Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 11. Global Primary Biliary Cirrhosis Drug Market Share by Application in 2022 & 2029
    Figure 12. Clinic
    Figure 13. Hospital
    Figure 14. Others
    Figure 15. Global Primary Biliary Cirrhosis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 16. Global Primary Biliary Cirrhosis Drug Market Size (2018-2029) & (US$ Million)
    Figure 17. Global Primary Biliary Cirrhosis Drug Sales (2018-2029) & (K Pcs)
    Figure 18. Global Primary Biliary Cirrhosis Drug Average Price (USD/Pcs) & (2018-2029)
    Figure 19. Primary Biliary Cirrhosis Drug Report Years Considered
    Figure 20. Primary Biliary Cirrhosis Drug Sales Share by Manufacturers in 2022
    Figure 21. Global Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers in 2022
    Figure 22. The Global 5 and 10 Largest Primary Biliary Cirrhosis Drug Players: Market Share by Revenue in 2022
    Figure 23. Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 24. Global Primary Biliary Cirrhosis Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 25. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2018-2029)
    Figure 26. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2018-2029)
    Figure 27. U.S. Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 28. Canada Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country (2018-2029)
    Figure 30. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2018-2029)
    Figure 31. Germany Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 32. France Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. U.K. Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 34. Italy Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 35. Russia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Region (2018-2029)
    Figure 37. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2018-2029)
    Figure 38. China Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 39. Japan Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. South Korea Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. India Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. Australia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. Taiwan Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 44. Indonesia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Thailand Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 46. Malaysia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 47. Philippines Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Latin America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2018-2029)
    Figure 49. Latin America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2018-2029)
    Figure 50. Mexico Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 51. Brazil Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 52. Argentina Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 53. Middle East & Africa Primary Biliary Cirrhosis Drug Sales Market Share by Country (2018-2029)
    Figure 54. Middle East & Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2018-2029)
    Figure 55. Turkey Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 56. Saudi Arabia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 57. UAE Primary Biliary Cirrhosis Drug Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 58. Global Sales Market Share of Primary Biliary Cirrhosis Drug by Type (2018-2029)
    Figure 59. Global Revenue Market Share of Primary Biliary Cirrhosis Drug by Type (2018-2029)
    Figure 60. Global Primary Biliary Cirrhosis Drug Price (USD/Pcs) by Type (2018-2029)
    Figure 61. Global Sales Market Share of Primary Biliary Cirrhosis Drug by Application (2018-2029)
    Figure 62. Global Revenue Market Share of Primary Biliary Cirrhosis Drug by Application (2018-2029)
    Figure 63. Global Primary Biliary Cirrhosis Drug Price (USD/Pcs) by Application (2018-2029)
    Figure 64. Primary Biliary Cirrhosis Drug Value Chain
    Figure 65. Primary Biliary Cirrhosis Drug Production Process
    Figure 66. Channels of Distribution (Direct Vs Distribution)
    Figure 67. Distributors Profiles
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Intercept Pharmaceuticals, Inc.
Johnson & Johnson
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.
Frequently Asked Questions
Primary Biliary Cirrhosis Drug report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Primary Biliary Cirrhosis Drug report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Primary Biliary Cirrhosis Drug report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports